Saturday, April 29, 2017 12:02:25 AM
"Our findings suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients, especially for those patients least likely to respond to checkpoint therapies. We are encouraged by the positive response and level of interest from within the industry."
"POSITVE RESPONSE AND LEVEL OF INTEREST" from within the industry. This is good. But just to prepare for all contingencies this is followed by considerable discussion,later in the proxy, of remedies for a hostile takeover!
Someone on another board suggested this latest cash raise might be part of regaining control of the Shattuck Lab spinoff...just as some of the previous cash raise went toward the Pelican merger. We know Shattuck Labs had "an international pharmaceutical company" take part in their latest private placement. I wonder which company this is? I wonder what their next move might be? A lot of questions!
"The refusal of the real is the number one dogma of our time" Rene Girard
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM